These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1059 related articles for article (PubMed ID: 16052573)

  • 1. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
    Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    Faurschou M; Westman K; Rasmussen N; de Groot K; Flossmann O; Höglund P; Jayne DR;
    Arthritis Rheum; 2012 Oct; 64(10):3472-7. PubMed ID: 22614882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
    Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C;
    N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
    Metzler C; Miehle N; Manger K; Iking-Konert C; de Groot K; Hellmich B; Gross WL; Reinhold-Keller E;
    Rheumatology (Oxford); 2007 Jul; 46(7):1087-91. PubMed ID: 17519271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.
    Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L;
    N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
    Haubitz M; Schellong S; Göbel U; Schurek HJ; Schaumann D; Koch KM; Brunkhorst R
    Arthritis Rheum; 1998 Oct; 41(10):1835-44. PubMed ID: 9778225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
    Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
    Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
    Tervaert JW; Stegeman CA
    Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
    Koldingsnes W; Nossent JC
    J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis (CYCLOPS study)].
    Kötter I
    Z Rheumatol; 2009 Sep; 68(7):575-7. PubMed ID: 19652987
    [No Abstract]   [Full Text] [Related]  

  • 13. [ANCA-associated vasculitis].
    Sinico RA; Sabadini E; Boeri R; Radice A
    G Ital Nefrol; 2002; 19(2):125-36. PubMed ID: 12195410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.
    Reinhold-Keller E; Fink CO; Herlyn K; Gross WL; De Groot K
    Arthritis Rheum; 2002 Jun; 47(3):326-32. PubMed ID: 12115164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
    Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.
    Langford CA; Talar-Williams C; Barron KS; Sneller MC
    Arthritis Rheum; 1999 Dec; 42(12):2666-73. PubMed ID: 10616016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis.
    Neumann I; Kain R; Regele H; Soleiman A; Kandutsch S; Meisl FT
    Nephrol Dial Transplant; 2005 Jan; 20(1):96-104. PubMed ID: 15546891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept plus standard therapy for Wegener's granulomatosis.
    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
    N Engl J Med; 2005 Jan; 352(4):351-61. PubMed ID: 15673801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.